

PATENT SPECIFICATION

5 TITLE: ANTICANCER POLYPEPTIDE-METAL COMPLEXES
AND COMPOSITIONS, METHODS OF MAKING,
AND METHODS OF USING SAME.

10 INVENTORS: WILLIAM W. ZUO
JINGYA XU
TONY DONGFANG YU
DAVID J. YANG

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to polypeptide-transition-metal complexes. In another aspect, the present invention relates to methods for making such polypeptide-transition metal complexes. In even another aspect, the present invention relates to compositions comprising polypeptide-transition-metal complexes and method of making such compositions.

25 In still another aspect, the present invention relates to methods of using such polypeptide-

transition-metal complexes and compositions comprising such complexes to treat a patient afflicted with a condition, such as for example a cancer in any stage of development.

5

2. Description of the Related Art

Improvement of cancer treatment is extensively determined by the development of more tumor specific pharmaceuticals and new drug delivery techniques. Due to an angiogenesis process involved in the tumor vasculature density and permeability, cell cycle regulation and cell signalling agents have opened a new era in the treatment of various tumors and undergone extensive development and evaluation.

15 Despite the outstanding advances made in the field of pharmacology, some significant limitations still remain in the treatment of various diseases via drug agents. One of the most significant limitations at this time relates to the delivery of particular

drugs *in vivo*, especially in situations where drugs are poorly water soluble. Indeed, the use of some drugs which show great promise *in vitro*, has been severely limited due to issues related to their solubility. This causes problems with drug delivery *in vivo*. One example of such a drug is cisplatin in the treatment of solid tumors.

As discussed below, the prior art has attempted to address this issue in a number of ways. However, as presented in more detail below, prior to the instant invention, the unique advantages of conjugating a transition-metal drug to one of the inventive polypeptides, while desired, were unknown.

United States Patent No. 4,675,381, issued to Bichon, on June 23, 1987, entitled "Biodegradable Polypeptide and its Use for the Gradual Release of Drugs," discloses a polyaspartate and/or polyglutamate polymer as a drug carrier. This patent envisions the use of polyaspartate and/or

polyglutamate polymers as drug carriers wherein the drug is encapsulated or incorporated in the matrix of the polymer. The patent does not disclose, teach or suggest metal complexes with the polymer.

5 Furthermore, most of the teaching in the patent is directed to homopolymers of aspartate or glutamate, not combinations of the two amino acids.

United States Patent No. 5,087,616 issued to Myers et al. on February 11, 1992, entitled "Cytotoxic Drug Conjugates and Their Delivery to Tumor Cells," discloses the use of a biodegradable polymeric carrier to which one or more cytotoxic molecules, for instance, daunomycin is conjugated. The biodegradable polymeric carrier is specified to be, for example, a homopolymer of polyglutamic acid. However, the use of a metal complexed with a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any

combinations thereof, is not disclosed, taught or suggested in this reference.

A 1983 *J Med Chem.* paper by Piper et al. entitled "A Synthetic Approach to Poly(γ -glutamyl) Conjugates of Methotrexate" discloses the use of methotrexate conjugated to 2 to 3 glutamic acid units. This paper does not disclose, teach or suggest a metal complex to a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof.

A 1982 *Int. J. Cancer* paper by Zunino et al. entitled "Anti-Tumor Activity of Daunorubicin Linked to Poly-L-Aspartic Acid" discloses daunorubicin bound to a homopolymer of polyaspartic acid. The paper indicates that "the binding (of daunorubicin) to the polypeptide markedly reduced drug toxicity but only slightly decreased drug potency." "The

daunorubicin-poly-L-aspartic acid conjugate demonstrated anti-tumor activity comparable to that of doxorubicin in leukemia models, but superior to that of doxorubicin in a solid tumor model." While this paper does disclose the covalent conjugation of an anti-tumor drug to a homopolymer of polyaspartic acid, it does not disclose, teach or suggest the use of a metal complex to a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof.

A 1998 *Cancer Research* paper by Li et al. entitled "Complete Regression of Well-established Tumors Using a Novel Water-soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate," discloses the use of a water-soluble poly-L-glutamic acid-paclitaxel conjugate to produce tumor effects with diminished toxicity. However, this paper does not disclose,

teach or suggest the use of the metal -polypeptide carrier complex of the present invention.

A 1989 *J. Pharm. Exp. Ther.* paper by Ramsammy entitled "Polyaspartic Acid Protects Against Gentamicin Nephrotoxicity in the Rat," discloses the use of poly-amino acids, including polyaspartic acid, to provide protection against the development of amino glycoside-induced nephrotoxicity in the rat. However, this paper does not disclose, teach or suggest the inventive a metal complex to a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof

A 1990 *Biopolymers* paper by Hayashi and Iwatsuki, entitled "Biodegradation of Copoly(L-Aspartic Acid/L-Glutamic Acid) *In Vitro*," discloses the preparation of copolypeptides consisting of L-aspartic acid and L-glutamic acid. The paper

describes the use of such polypeptides to determine the effects of copolymer composition and sequential distributions on the rate of degradation by papain to stimulate *in vivo* polymer degradation. This paper does disclose, teach or suggest the use of copolymers of glutamic acid and aspartic acid, similar to the copolymer of the present invention.

The paper also does not disclose, teach or suggest the use of a metal complex to a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof.

United States Patent No. 4,960,790 issued to Stella et al., and entitled "Derivatives of Taxol, Pharmaceutical Compositions Thereof and Methods for the Preparation Thereof" discloses the anti-tumor agent taxol covalently conjugated with, for example, an amino acid (for example, glutamic acid).

However, this patent does not disclose, teach or suggest the use of a metal complex to a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof.

Finally, a 1960 *J. Am. Chem. Soc.* by Karlson et al., entitled "The Helical Sense of Poly- β -benzyl-L-aspartate" discusses the physical characteristics of series of copolymers derived from γ -benzyl-L-glutamate and β -benzyl-L-aspartate. However this paper does not disclose, teach or suggest the use of a metal complex to a polypeptide carrier comprising glutamic acid and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof.

As indicated from the above art, there exists a long-felt need in the art to solubilize poorly soluble drugs, such as anti-tumor agents. Thus,

there is a need in the art for therapeutic compounds comprising a transition metal drug wherein the compounds have improved solubility in comparison to conventional transition metal drugs.

5 There is another need in the art for methods of making such therapeutic compounds.

There is even another need in the art for compositions comprising such therapeutic compounds.

There is still another need in the art for methods of making such compositions.

There is yet another need in the art for methods for treating a patient afflicted with a condition such as a cancer in any stage of development.

TOP SECRET - DRAFT

SUMMARY OF THE INVENTION

It is an object of the present invention to provide therapeutic compounds comprising a transition metal drug wherein the compounds have improved solubility in comparison to conventional transition metal drugs.

It is another object of the present invention to provide methods of making such therapeutic compounds.

It is even another object of the present invention to provide for compositions comprising such therapeutic compounds.

It is still another object of the present invention to provide methods of making such compositions.

It is yet another object of the present invention to provide methods for treating a patient afflicted with a condition such as a cancer in any stage of development.

According to one embodiment of the present invention there is provided a therapeutic compound comprising at least one therapeutic metal, and at least one polypeptide carrier moiety, the metal complex to the carrier moiety, and the polypeptide drug carrier moiety comprising glutamic acid and a second amino acid selected from the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and combinations of two or more amino acids selected from the group consisting of aspartic acid, alanine, asparagine, glutamine, and glycine. A preferred second amino acid is aspartic acid.

Generally the polypeptide drug carrier moiety comprises from about 50 to about 90 percent, by total weight of the carrier, glutamic acid, and from about 10 to about 50 percent, by total weight of the carrier, aspartic acid, or alanine, or asparagine, or glutamine, or glycine, or combinations thereof; more preferably from about 60 to about 80 percent,

by total weight of the carrier, glutamic acid, and from about 20 to about 40 percent, by total weight of the carrier, aspartic acid, or alanine, or asparagine, or glutamine, or glycine, or combinations thereof; and most preferably from about 5 70 to about 75 percent, by weight, glutamic acid, and from about 25 to about 30 percent, by weight, aspartic acid, or alanine, or asparagine, or glutamine, or glycine, or combinations thereof.

Generally the drug moiety is selected from the group consisting of therapeutic metals. Preferably, the therapeutic metals are platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium or rhodium. A preferred drug moiety is 15 platinum.

Generally the drug moiety of the therapeutic metal comprises from about 10 percent to about 60 percent, by weight, more preferably from about 20 percent to about 50 percent, by weight, and most

preferably from about 20 percent to about 40 percent, by weight of the therapeutic compound. Moreover, the polypeptide carrier moiety may comprise from about 40 percent to about 90 percent, by weight, more preferably from about 50 percent to about 80 percent, by weight, and most preferably from about 60 percent to about 80 percent, by weight of the therapeutic anticancer peptide-metal complex.

According to another embodiment of the present invention there is provided methods for making a therapeutic compound. Generally

According to even another embodiment of the present invention there is provided a composition comprising a therapeutic compound.

According to still another embodiment of the present invention there is provided a method for making a composition comprising a therapeutic compound.

According to yet another embodiment of the

present invention there is provided a method for
treating cancer comprising the steps of
administering a therapeutically effective amount of
an anticancer peptide comprising at least one metal,
5 and at least one polypeptide drug carrier moiety,
the metal being covalently chelated to the carrier
moiety, and the polypeptide drug carrier moiety
comprising glutamic acid and a second amino acid
selected from the group consisting of aspartic acid,
10 alanine, asparagine, glutamine, glycine, and
combinations of aspartic acid, alanine, asparagine,
glutamine, and glycine.

These and other embodiments of the present
invention will become apparent to those of skill in
15 the art upon review of this specification, including
its drawings, appendix, and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a schematic illustrating the synthesis of a poly(glutamidaspatic acid) polypeptide.

5 Figure 1B provides results from an amino acid analysis of a sample of the poly(glutamic/aspartic acid polypeptide.

10 Figure 1C shows an NMR spectra of a sample of poly(glutamate/aspartame).

Figure 2 is a synthetic scheme illustrating platinum (II)- and (IV)-poly(glutamate/aspartame) complexes.

15 Figure 3 shows elemental analysis of the platinum-poly(glutamate/aspartate) complexes Pt(II) (PDDP) , Pt(IV) (PPAP) , and cis-1,2-DACH-Pt SO₄ (DACH) .

Figures 4A-C shows results from *in vitro* cell

culture assays of cisplatin (CDDP) and poly(glutamate/aspartate) acid-1,2-DACH-Pt (II) complex (PDDP) in sarcoma (4A) and prostate cancer cell lines (4B and 4C).

5

Figure 5 shows the *in vivo* antitumor activity of an inventive poly(glutamate/aspartate)-1,2-DACH-Pt (II) complex compared to saline (control) in rats bearing breast tumors.

卷之三

Figure 6 shows specific cellular target expression changes at 48 hours post treatment of cells with poly(glutamate/aspartate)-1,2-DACH-Pt (II) complex (PDDP), cisplatin (CDDP), and saline (Control).

15

Figure 7 shows histopathological changes at 48 hours post treatment of poly(glutamate/aspartate)-1,2-DACH-Pt (II) complex (PDDP), cisplatin (CDDP), and saline (Control). A marked necrosis and apoptosis

were noted post-treatment.

09/04/2000 10:22:20
TODAY'S DATE

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the discovery that polypeptides composed of glutamate and at least of the group consisting of aspartate, alanine, asparagine, glutamine, glycine, and any combinations thereof, make an unexpectedly good carrier for delivery of therapeutic metals, including poorly soluble drugs. An illustrative example includes a polypeptide-platinum complex. The inventive complex of the present invention comprising a metal conjugated to a polypeptide to increase metal solubility *in vivo*, while desired in the art, has not been anticipated or suggested by the art.

The polypeptide-metal complexes of the invention have improved water solubility, reduced side effects, and are more effective against tumors in comparison to conventional metal drugs. Preferably, the water solubility of the therapeutic anticancer peptide-metal complex is greater than the water

solubility of the metal alone. Generally the polypeptide comprises glutamic acid with at least one of the group consisting of alanine, aspartic acid, glycine, glutamine, asparagine, and any combinations thereof. Generally, the drug moiety is 5 a therapeutic metal and may be selected from the group consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium and rhodium. In a preferred embodiment, the drug moiety is platinum.

As described in more detail below, the present inventors have discovered that the use of a polypeptide drug carrier comprising glutamate and at least one of the group consisting of aspartate, 15 alanine, asparagine, glutamine, glycine, and any combinations thereof, results in unexpectedly good *in vivo* properties when complexed with metals.

Preferred polypeptides of the invention include poly-glutamate/aspartate and poly-glutamate/

alanine, asparagine, glutamine, glycine. In particular, and for example, one use of the instant invention involves the complex of platinum to a polypeptide of the invention to enable the effective 5 *in vivo* treatment of cancer.

Regarding the role of alanine, asparagine, glutamine, and/or glycine in the present invention, the following is noted. It is believed at the time of the application that a polypeptide comprising glutamate and aspartic acid is a preferred polypeptide of the invention. However, it is also believed, but not in any limiting sense, that any amino acids similar to aspartic acid, including alanine, asparagine, glutamine, and glycine, can be substituted for aspartic acid in the inventive polypeptide. While not wishing to be bound in anyway, it is believed that a key aspect of the inventive polypeptide relates to the glutamic acid backbone. It is believed that as long as glutamic 15

acid is present in the polypeptide, aspartic acid may serve as the other amino acid, or any amino acid similar to aspartic acid, such as, for example, alanine, asparagine, glutamine, glycine, and any combinations thereof may be used. These amino acids 5 may be substituted in whole or in part for aspartic acid and may be a combination of at least any two of these amino acids. Thus, the present invention provides a plurality of inventive polypeptide polymers, each having glutamic acid, and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof.

One embodiment of the present invention relates 15 to a therapeutic compound comprising at least one drug moiety, and at least one polypeptide drug carrier moiety, the drug moiety being complexed to the carrier moiety, and the polypeptide drug carrier moiety comprising glutamic acid and a second amino

acid selected from the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and combinations thereof. Generally the drug moiety is selected from the group consisting of therapeutic metals. Preferably, the therapeutic metals are platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium or rhodium. A preferred drug moiety is a platinum analogue.

Conditions to be treated may include, but are in no way limited to, prostate, breast, ovarian, colon, leukemia, lymphoma, sarcoma, head and neck, lung and liver cancers, and any combinations thereof. The condition may be in any stage of development.

Based on the total weight of the polypeptide drug carrier moiety, generally the polypeptide drug carrier moiety comprises glutamic acid in an amount ranging from about 50 to about 90 percent, preferably from about 60 to about 80 percent, and more preferably from about 70 to about 75 percent.

Based on the total weight of the polypeptide drug carrier moiety, generally the polypeptide drug carrier moiety comprises at least a second amino acid in an amount ranging from about 10 to about 50 percent, preferably from about 20 to about 40 percent, and more preferably from about 30 to about 25 percent. The at least second amino acid is selected from the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and all combinations thereof.

Based on the total weight of the therapeutic compound (i.e., the therapeutic peptide-metal complex), the therapeutic compound generally comprises a metal moiety in an amount ranging from about 10 percent to about 60 percent, more preferably from about 20 percent to about 50 percent, and most preferably from about 20 percent to about 40 percent. Based on the total weight of the therapeutic compound (i.e., the therapeutic

peptide-metal complex), the therapeutic compound generally comprises the polypeptide drug carrier moiety in an amount ranging from about 40 percent to about 90 percent, more preferably from about 50 percent to about 80 percent, and most preferably from about 60 percent to about 80 percent.

In preferred embodiments, for example, platinum with a polypeptide glutamic acid/aspartic acid carrier), the metal moiety does not comprise more than about 60% by weight of the therapeutic anticancer peptide-metal complex (in order to not adversely affect solubility and/or viscosity which can effect injectability of the compound).

In a particularly preferred embodiment, therapeutic polypeptide-drug complex/compound comprises a molecular weight of about 20,000 to about 50,000 dalton, a platinum drug moiety in an amount ranging from about 20 to about 40 percent based on the total weight of the compound, and a

carrier moiety comprising about 70 percent glutamic acid based on the total weight of the carrier moiety, and about 30 percent aspartic acid based on the total weight of the carrier moiety.

5 Another embodiment of the present invention is directed to a method for making a therapeutic compound. Generally the method comprising the steps of covalently conjugating at least one drug moiety with at least one polypeptide drug carrier moiety to create a therapeutic polypeptide-metal complex of the invention. Generally based on the total weight of the carrier moiety, the carrier moiety comprises from about 50% to about 90% glutamic acid, and from about 10% to about 50% of at least a second amino acid selected from the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and any combinations thereof. Preferably the second amino acid is aspartic acid. Generally the drug carrier moiety has a molecular weight from about

20,000 daltons to about 50,000 dalton, and the drug moiety is a therapeutic metal selected from the group consisting of platinum, iron, gadolinium, rhenium, manganese, cobalt, indium, gallium or rhodium. Preferably the drug moiety is platinum, such as 1,2-diaminocyclohexane platinum (II) and 1,2-diaminocyclohexane-dichloro platinum (IV). In particularly preferred therapeutic compound of the invention the carrier moiety comprises about 70 percent glutamic acid and about 30 percent aspartic acid based on the total weight of the carrier moiety, the drug moiety is about 24 percent to about 30 percent by weight of the total weight of the therapeutic compound, the drug moiety is platinum (II) and platinum (IV), and the molecular weight of the therapeutic compound is from about 26,000 to about 30,000 dalton.

Even another embodiment of the present invention is directed to a composition comprising a

therapeutic compound. The therapeutic compound may be any of the polypeptide-metal complexes of the present invention. Suitable compositions of the invention are described in detail in the Dosage and

5 Formulation section of the present application.

Still another embodiment of the present invention is directed to a method for making a composition. Generally the method comprises the steps of combining a pharmaceutical carrier with a therapeutic compound of the invention. Suitable carriers are described in detail in the Dosage and Formulation section of the present application.

Yet another embodiment of the present invention is directed to a method for treating a patient afflicted with a condition. Generally the method comprises the step of administering a therapeutically effective amount of a therapeutic compound of the present invention to a patient. Treatment methods, modes of administration and

dosages are described in detail in the Dosage and Formulation section of the present application.

Even still another aspect of the present invention relates to a method for improving the solubility of a drug moiety comprising the metal.

5 In a preferred embodiment, the water solubility of the therapeutic compound is greater than the water solubility of the metal alone. In a preferred embodiment, the drug moiety may be platinum analogue.

10 As used herein, the term "therapeutic", for example, in the phrases "therapeutic compound" and "therapeutically effective amount" means to have at least some minimal physiological effect. For example, a "therapeutic compound" would have at least some minimal physiological effect upon being administered to a living body / patient. An agent 15 may have at least some minimal physiological effect upon administration to a living body if, for

example, administration results in a change in the physiology of the recipient animal. For example, a physiological effect upon administering a "therapeutic" anti-tumor compound may be the inhibition of tumor growth, or decrease in tumor size, or prevention of reoccurrence of the tumor.

5 Administration of a "therapeutically effective amount" means the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a change in the physiology of a recipient animal.

10 For example, in the treatment of cancer or neoplastic disease, a compound which inhibits the growth of a tumor or decreases the size of the tumor or prevents the reoccurrence of the tumor would be

15 considered therapeutically effective.

The term "anti-tumor drug" as used herein means any therapeutic agent having therapeutic effect against a tumor, neoplastic disease or cancer.

The term "metal" as used herein means metal having a therapeutic effect when administered to an animal.

The preferred dosage of the present administration for therapeutic treatment is a therapeutically effective dosage/amount of the administered agent sufficient to generate a response when administered to the patient.

卷之三

15

The term "treating", as used herein, for example in the term "treating a condition", means at least the administration of a therapeutically effective amount of a therapeutic compound to elicit a therapeutic effect. It does not necessarily imply "curing", but rather implies that the administration of the present invention to a living body afflicted with a condition results in at least some minimal physiological effect upon the condition. For example, treatment could encompass administering an agent wherein the presence of that agent results in

a change in the physiology of the recipient animal.

The terms "peptide", "polypeptide", "di-peptide", "copolymer", "poly(glutamic acid/aspartic acid)" (and all variations thereupon), and "inventive peptide", refer to the peptide of the present invention as further defined herein (and comprising, for example, a polypeptide comprising aspartic acid and glutamic acid and/or polypeptides comprising aspartic acid with alanine, asparagine, glutamine and glycine, in any combination).

The term "patient" as used herein refers to the recipient to whom the present invention is administered. The patient may be any organism capable of developing cancer, or afflicted with a cancer wherein the cancer is in any stage of development. Preferably, the patient of the invention is a mammal. In a particularly preferred embodiment, the patient is a human.

Dosage and Formulation

The therapeutic compounds (including compounds, drugs, conjugates and the like, as well as compositions comprising the inventive polypeptide-metal complexes,) of this invention can be formulated and administered to treat a variety of conditions. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a composition comprising a combination of therapeutic active ingredients. They can be administered alone, or with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosages are determined for the chosen therapeutic use, including the condition to be treated, the therapeutic agent used to treat the condition and the type of animal treated (including

considerations as to age, weight, sex and so forth).

Such determinations are well within the scope of those skilled in the art and do not involve undue experimentation or exercise of inventive skill.

5 The dosage administered will be a therapeutically effective amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired. Usually a daily dosage (therapeutic effective amount) of active ingredient can be about 1 to 400 milligrams per kilogram of body weight. Ordinarily, 1 to 200, and preferably 1 to 50, milligram per kilogram per day given in dividend doses 2 to 4 times a day or in sustained release form is effective to

obtain desired results.

Dosage formulations (compositions) suitable for internal administration contain from about 1.0 to about 500 milligrams of active ingredient per unit.

5 In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.05-95% by weight based on the total weight of the composition.

10 Administration may be by any means suitable for the condition to be treated and may include, for example, oral administration. Such determination is within the ordinary level of skill of one skilled in the art. For example, oral administration may be accomplished using solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions.

15 The therapeutic compound (agent, composition, or the like) may also be, for example, parenterally

administered by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption. The agent may also be administered intramuscularly, intravenously, or as a suppository.

5 Gelatin capsules may contain the therapeutic compound and powdered carriers such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste 15 and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

 Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient

acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration may contain a water soluble salt of the therapeutic compound (agent and the like), suitable stabilizing agents and, if necessary, buffer substances. Antioxidizing agents such as sodium bisulfate, sodium sulfite or ascorbic acid either alone or combined are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-prarben and chlorobutanol. Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field.

Additionally, standard pharmaceutical methods

can be employed to control the duration of action.

These are well known in the art and include control release preparations and can include appropriate macromolecules, for example polymers, polyesters, polyaminoacids, polyvinylpyrrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate. The concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release. Additionally, the agent can be incorporated into particles of polymeric materials such as polyesters, polyaminoacids, hydrogels, poly(lactic acid) or ethylenevinylacetate copolymers.

In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.

Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.

Capsules: Capsules may be prepared by filling

standard two-piece hard gelatin capsules each with
from about 50 mg to about 150 mg, preferably about
100 mg of powdered active ingredient, about 150 mg
to about 200 mg, preferably about 175 mg of lactose,
about 15 mg to about 30 mg, preferably about 24 mg
of talc and about 1 mg to about 15 mg, preferably
about 6 mg magnesium stearate.

Soft Gelatin Capsules: A mixture of active
ingredient in soybean oil may be prepared and
injected by means of a positive displacement pump
into gelatin to form soft gelatin capsules
containing from about 50 to about 150 mg, preferably
100 mg of the active ingredient. The capsules are
then washed and dried.

Tablets: Tablets may be prepared by
conventional procedures so that the dosage unit is
from about 50 mg to about 150 mg, preferably about
100 mg of active ingredient, 0.1 to about 0.5 mg,
preferably about 0.2 mg of colloidal silicon

dioxide, from about 1.0 mg to about 10 mg, preferably about 5 mg of magnesium stearate, from about 200 to about 300 mg, preferably about 275 mg, of microcrystalline cellulose, about 5 to about 15 mg, preferably about 11 mg of cornstarch and about 75 to about 120 mg, preferably about 98.8 mg of lactose. Appropriate coatings may be applied to increase palatability or to delay absorption.

Injectable: A parenteral composition suitable for administration by injection is prepared by stirring about 1.0 to about 5.0 % by weight, preferably about 1.5% by weight, of active ingredients in about 5 to about 20 % by volume, preferably about 10% by volume, propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

Suspension: An aqueous suspension is prepared for oral administration so that from about 1 to about 10 ml, preferably about 5 ml contain about 50

to about 150 mg, preferably about 100 mg of finely divided active ingredient, about 150 to about 250 mg, preferably about 200 mg of sodium carboxymethyl cellulose, about 2 to about 10 mg, preferably about 5 mg of sodium benzoate, about 0.1 to about 5 g, preferably about 1.0 g of sorbitol solution U.S.P. and from about 0.01 to about 0.1 ml, preferably about 0.025 ml of vanillin.

SEARCHED
INDEXED
FILED
TYPED
RECORDED

The amino acids useful in the polypeptides of the present invention may be D amino acids, L amino acids, or mixtures of D and L amino acids. Further, it is contemplated that the carrier polypeptide of the present inventive complexes need not exclusively contain an individual polypeptide containing solely the combination of glutamic and at least one of the group consisting of aspartic acid, alanine, asparagine, glutamine, glycine, and all combinations thereof. Rather, while sections of the polypeptide may contain the noted combination of amino acids, it

is believed that it is not necessary for the entire peptide to homogeneously include only the noted amino acids, especially not necessarily in repeating monomers. Thus, the carrier may comprise components other than the noted amino acids, providing that at least some of the carrier polypeptide is composed of the inventive combinations of amino acids.

It is readily apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All references cited in the present application, including journal articles, laboratory manuals, all U.S. and foreign patents and patent applications, are specifically and entirely incorporated by reference.

EXAMPLES

5

The following examples are provided to illustrate the present invention. These examples are not intended to limit the scope of the claims of the present invention, and should not be so interpreted.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9445
9450
9455
9460
9465
9470
9475
9480
9485
9490
9495
9500
9505
9510
9515
9520
9525
9530
9535
9540
9545<br

as the treatment of cancer.

Platinum was selected to serve as an exemplary embodiment of a drug to be conjugated with the inventive carrier because platinum is known in the art to be an antitumor drug and known to have solubility problems *in vivo*. Hence, it has known effectiveness problems and toxicity problems *in vivo* related to its stability and related *in vivo* use. Furthermore, the need for the present invention (i.e., a carrier that can solubilize and/or enhance the *in vivo* therapeutic use of drugs, for example, poorly soluble drugs, such as, for example, poorly soluble antitumor drugs) is amply demonstrated by platinum since as discussed in the background of the present application, there have been numerous attempts in the prior art to conjugate the drug to various carriers, including polypeptides, in attempts to improve the biological applicability of platinum.

The effectiveness of platinum complexes against tumor activity has been demonstrated. For instance, cisplatin, a widely used anticancer drug, has been used alone or in combination with other agents.

5 Cisplatin causes cell arrest at S-phase and that leads to mitotic arrest of proliferating cells.

Cisplatin also decreases expression of vascular endothelial growth factor (VEGF) during chemotherapy. Cisplatin is effective in the treatment of majority solid tumors. However, its clinical applications are associated with significant nephrotoxicity, myelosuppression, drug resistance, gastrointestinal toxicity, neurotoxicity and other side effects (e.g. vomiting,

15 granulocytopenia and body weight loss. Cisplatin is formulated in the bulky vehicles and has been used to treat breast, ovarian, colon and lung cancers.

Its poor water solubility greatly impairs its therapeutic efficacy. Chemical modification of

cisplatin may increase its hydrophilicity, reduce its side effect, and improve its therapeutic efficacy. However, because of the chemical inertness of platin, modification of platin derivatives to be more potent and to have better water solubility than cisplatin has been less demonstrated.

Platinum was, therefore, chosen, as an exemplary drug in which to complex to the inventive glutamic acid/aspartic acid polypeptide in order to determine whether conjugation in the inventive complex produces a drug carrier complex which shows improved therapeutic use.

15

Example 1

Synthesis of Polypeptide: Poly(glutamate/aspartate)

N-carboxyanhydride (NCAs) was prepared by phosgenation (a procedure known in the art) of the

corresponding β -benzyl-l-aspartate and γ -benzyl-l-glutamate (Idelson, M., Blout, E.R., *J. Am. Chem. Soc.* **1958**, 80, 2387-2393; Karlson, R.H., Norland, K.S., Fasman, G.D., Blout, E.R., *J. Am. Chem. Soc.* **1960**, 82, 2268-2278; Paolillo, L., Temussi, P.A., Bradbury, E.M., Crane-Robinson, C. *Biopolymers*, **1972**, 11, 2043-2052; Hayashi, T., Iwatsuki, M., *Biopolymers*, **1990**, 29, 549-557; Bradbury, E.M., Carpenter, B.G., Crane-Robinson, C., Goldman, H., *Macromolecules*, **1971**, 4, 557-564.).

Briefly, a solution of phosgene (10% w/v) was bubbled into ethylacetate (150 ml). An aliquot (10 ml) of this solution was added to 10 grams of finely ground β -benzyl-l-aspartate and γ -benzyl-l-glutamate in ethylacetate (150 ml). The reaction was stirred under reflux for 5 mm. A stream of nitrogen was employed to remove excess HCl prior to the next addition of phosgene. The sequence was repeated until no traces of suspended amino acid HCl

remained. The mixture was then filtered and the solvent was evaporated in vacuo. The product was crystallized from ethyl acetate.

Solutions of NCAs of β -benzyl-l-aspartate and γ -benzyl-l-glutamate in dioxane/methylene chloride (1:3) were prepared. The ratios (w/w) used between δ -benzyl-l-aspartate and γ -benzyl-l-glutamate were 3:7, 2:8 and 1:9. The polymerization was initiated with triethylamine in methylene chloride (4 ml, 2.5% v/v). The copolymerization reaction was under reflux for 30 min and followed by CO_2 evolution. The reaction was stopped at about 30 mol % conversion. The polymers formed were precipitated by adding ice cold methanol containing 0.1N HCl (5% v/v). The products were washed with methanol and dried under reduced pressure, yielded 8gm (for 3:7 batch). The debenzylation was conducted by using HBr according to a known procedure (Idelson, M.; Blout, E.R., *J. Am. Chem. Soc.* 1958, 80, 2387-2393). After HBr

treatment, the aqueous solution was dialyzed against distilled water, filtered through Millipore filter and lyophilized. Typical average molecular weight was 26,000-30,000 daltons. A synthetic scheme is shown in Figure 1A. A similar technique was used to prepare polymers of glutamic acid and alanine, glutamic acid and asparagine, glutamic acid and glutamine, glutamic acid and glycine, and glutamic acid and one or more amino acids from the group consisting of aspartic acid, alanine, asparagine, glutamine, and glycine.

Amino acid analyzer (PE/ ABI 420 A) (Foster City, CA) was used to determine the actual composition ratio of aspartic acid and glutamic acid. Briefly, 15 polypeptide was hydrolyzed with HCl (6N) at 150 °C for 75 min. The hydrolyzed products were loaded on PVDF membrane and methanol (30%) and HCl (0.1N, 0.2 ml) were added to extract the amino acids. Using pre-column derivatization with phenylisothiocyanate,

the amino acid concentration was determined. An amino acid analysis of the poly(glutamic acid/aspartic acid) is shown in Figure 1B. Figure 1C provides the results of NMR analysis on a sample of the poly(glutamic/aspartic acid) polypeptide.

5

Example 2 Synthesis of Poly(glutamate/aspartate) -

platinum analogue (II) and (IV) complex

10 Numerous studies have suggested that limited polymer-drug conjugate discretion through the kidneys is evident when the molecular weight of the conjugate ranges from 20,000 to 50,000 daltons. Thus, to enhance tumor uptake of the platinum 15 analogue-inventive carrier conjugate, a molecular weight range of a conjugate of 26,000 to 30,000 daltons was selected. It is suggested that Pt (IV) complex exerts its anticancer effect via in vivo reduction to Pt (II) complex. Thus, it is

anticipated that Pt (II) is more potent than Pt (IV). Therefore, both Pt (II) and Pt (IV) were synthesized and bound to poly(glutamic/aspartic acid) polypeptide.

5 Cis-1,2-Diaminocyclohexane sulfatoplatinum (II) (cis-1,2-DACH-Pt_xSO₄) was synthesized via a two-step procedure. Cis-1,2-DACH-PtI₂ complex was synthesized by mixing a filtered solution of K₂PtCl₄ (5.00g, 12 mmol) in 120 ml of deionized water with KI (20.00g in 12 ml of water, 120 mmol) and was allowed to stir for 5 min. To this solution one equivalent of the cis-1,2-DACH (1.37g, 1.487 ml, 12 mmol) was added. The reaction mixture was stirred for 30 min at room temperature. A yellow solid was obtained which was separated by filtration, washed with a small amount of deionized water. The final product was dried under vacuum, yielded cis-1,2-DACH-PtI₂ (6.48g, 96%). Without further purification, cis-1,2-DACH-PtI₂ (6.48g, 11.5 mmol) was added as a solid to an

aqueous solution of Ag_2SO_4 (3.45g, 11 mmol). The reaction mixture was left stirring overnight at room temperature. The AgI was removed by filtration and the filtrate was freeze dried under vacuum, yielded 5 yellow $\text{cis-1,2-DACH-Pt(II)SO}_4$ (4.83g, 99%). Elemetal analysis Pt: 44.6% (w/w).

Conjugation of platinum (II) analog $\text{cis-1,2-DACH-Pt\cdot SO}_4$ to poly(glutamate/aspartate) was conducted as follows: $\text{Cis-1,2-DACH-Pt\cdot SO}_4$ (500mg, 1.18 mmol) was dissolved in 10 ml of deionized water, and a solution of sodium poly(glutamic/aspartic acid) (1.00g; Glu:Asp; 7/3) in 15 ml of deionized water was added. The solution was left stirring for 24 hr at room temperature. After dialysis (MWCO:10,000) and lyophilization, the yield of $\text{cis-1,2-DACH-Pt(II) - poly(glutamic/aspartic acid)}$ was 1.1462g. 15 Elemetal analysis Pt: 17.64% (w/w).

$\text{Cis-1,2-DACH-dichloro-Pt(IV) - poly(glutamic/aspartic acid)}$ was synthesized as

follows: the above solution was added dropwise 2.5 ml of 30% aqueous hydrogen peroxide. After 24 hr, HCl(75ml of 0.02 N) was added and left stirring for 24 hr at room temperature, dialyzed (MWCO:10,000) by deionized water for overnight, freeze dried under vacuum. The final product obtained was 1.15g. Elemental analysis Pt: 16.11% (w/w) .

Figure 2 provides the structures of the Pt(II) and Pt(IV) complexes, and Figure 3 provides the results of elemental analysis of platinum-poly(glutamate/aspartate) complexes Pt(II) (PDDP) , Pt(IV) (PPAP) , and cis-1,2-DACH-Pt SO₄ (DACH) .

Example 3 In vitro cell culture assay:

To evaluate cytotoxicity of cisplatin and platinum (II) and (IV) polypeptide complex against mammary tumor cells, three human tumor cell lines were selected: PC3 (prostate); A10 (prostate); and

sarcoma. All cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂ in Eagle's medium. Forty-eight hours prior to the experiment, the cells were transferred to 35 mm culture dishes at 5 x 10⁵ cells per dish and grown to 80% confluence. Cultured human tumor cells in 35 mm dishes were incubated with either cisplatin or platinum (II) and (IV) polypeptide complex at various concentrations. The incubation was stopped at 72 hours. Methylene tetrazolium (MTT) dye assay determined the amount of viable cells. Cellular protein content was determined by Lowry assay. The drug concentration that inhibits 50% of cell growth was then determined.

15 Figures 4A-C shows results from *in vitro* cell culture assays of cisplatin (CDDP) and poly(glutamate/aspartate) acid-1,2-DACH-Pt (II) complex (PDDP) in sarcoma (4A) and prostate cancer cell lines (4B and 4C).

Example 4 Evaluation of the conjugates in four tumor-
bearing animal models

Cisplatin is known to produce an anticancer
5 effect against breast and ovarian tumors.
Therefore, four animal models were selected:
ovarian, breast and two prostate cancer models. The
breast and ovarian animal models were driven from
animal tumor cell lines, the prostate models were
created using human cell lines xenografted in nude
mice. An illustrated Poly(glutamate/aspartate)-
platinum analogue (II) complex against breast tumor
growth curve is shown in Figure 5.

15 Breast tumor-bearing animal model:

Female Fischer 344 rats (125-175g) were
inoculated with breast cancer cells (13762NF, 10^6
cells/rat, s.c. in the hind leg). After 15-20 days
and a tumor volume of 1 cm, the breast tumor-bearing

rats were administered either the platinum peptide complex or cisplatin at doses of 43 mg Pt/kg (peptide platinum II) or 12 mg/kg (cisplatin).
5 Tumor volumes and body weight were recorded daily for sixty days. Tumor volumes were measured as [length (l) x width (w) x thickness (h)]/2. Loss of body weight of 15% is considering a chemical-induced toxic effect. The results are shown in Figure 5 and indicate that the inventive platinum peptide complexes are all effective *in vivo* against breast cancer.

Example 5 Imunohistopathology of tumor tissue after treatment:

15

After treatment with either cisplatin or the platinum peptide complex, tumor tissues (breast) were dissected and embedded in formalin. The tumor tissue was fixed in paraffin and stained for

cellular target expression. The result is shown in Figures 6 and 7.

Figure 6 shows specific cellular target expression changes at 48 hours post treatment of cells with poly(glutamate/aspartate)-1,2-DACH-Pt (II) complex (PDDP), cisplatin (CDDP), and saline (Control). Figure 7 shows histopathological changes at 48 hours post treatment of poly(glutamate/aspartate)-1,2-DACH-Pt (II) complex (PDDP), cisplatin (CDDP), and saline (Control). A marked necrosis and apoptosis were noted post-treatment.

In summary, a new polypeptide based water soluble platinum complex is developed. The solubility is increased up to 20 mg/ml. The half-life of *in vitro* stability in phosphate buffered saline (pH 7.4) is 18 days. The product is easily scaled up and prepared as a sterilized powder. Compared to cisplatin, insignificant toxicity was

observed and much higher initial loading dose could be administered intravenously. The product produced significant anticancer effects in cancer models.